top of page

Diabetic Foot Ulcer
(Heberprot - B)

In Cuba, Heberprot-P is administered for patients with a poor prognosis, chronic non-healing wounds and patients who do not respond to conventional treatment methods.

sterm-cell-theraphy-47.png

Heberprot-P is a drug developed by the Center for Genetic Engineering and Cuban Biotechnology in Cuba for the treatment of severe diabetic foot ulcers. Its main component is epidermal growth factor (EGF) and is administered parenterally (intralesional injection directly into the wound). Approximately 160,000 diabetic foot ulcer patients have been treated with Heberprot-P and 75% have been successful in eliminating the risk of amputation.


The concentration of growth factors, especially epidermal growth factor receptor (EGF), is reduced in diabetic patients.EGF is an important growth factor that regulates cell growth and cell increase by binding to epidermal growth factor receptors (EGFR) in diabetic foot patients. When the amount of EGF is reduced, the healing of wounds from diabetic foot ulcers is greatly reduced and amputation may eventually be necessary. When Heberprot-P is applied in Cuba, the recovery time increases continuously and progressively.

In Cuba, Heberprot-P is administered for patients with diabetic foot ulcers with poor prognosis, chronic non-healing wounds and unresponsive to conventional treatment methods.

Each treatment program is regulated by the Cuban Ministry of Health, depending on the severity of the condition and the overall health of the patient.

Registration is easy.  Follow the steps and we will get in touch with you shortly to advise you further.

bottom of page
$w.onReady(function () { let mylink=$w('#aramabuttonu'); let numbers=['tel:+905531701145','tel:+905531701045','tel:+905521875101','tel:+905521875100']; let rastgele=Math.floor(Math.random()*4); mylink.link=numbers[rastgele]; });